Eye Area Regulatory Requirements: EU, FDA & NMPA Periorbital Product Guidelines

Overview #

The eye area is not just another zone on the face. The periorbital skin is 0.5 mm thick — roughly one-third the thickness of cheek skin — and it has almost no sebaceous glands to buffer against irritation. That physical reality shapes every formulation decision we make, from pH target to preservative selection to viscosity. When a brand brief lands on our desk asking for an “eye cream,” the first thing we do is not reach for an ingredient list. We ask: which market? Which claims? Because the regulatory gap between EU, FDA, and NMPA for periorbital products is wide enough to sink a launch if you don’t plan for it from day one.

How We Read a Periorbital Brief — And What We’re Actually Asking #

When a brand partner walks into a kickoff meeting with an eye product brief, the conversation usually starts with aesthetics — texture, finish, packaging. We redirect it fast.

The first question is always: what claims are you putting on pack? That single answer determines whether we’re formulating a cosmetic or walking into quasi-drug territory. Under EU Cosmetics Regulation 1223/2009, any claim implying structural change to the skin — “reduces deep wrinkles,” “rebuilds collagen” — can trigger scrutiny from notified bodies. In the US, the FDA Cosmetics Guidelines draw a similar line: cosmetics alter appearance, drugs affect structure or function. Cross that line with your copy and you’ve changed your regulatory pathway entirely.

China is a different conversation. Under NMPA Cosmetic Regulation, eye-area products fall under special-use cosmetics if they carry functional claims, which means pre-market registration, not just notification. That adds 6–12 months to your China launch timeline. Most brands don’t factor that in until we tell them.

The second question is: what’s your target consumer’s skin profile? Periorbital skin in a 55-year-old with compromised barrier function behaves completely differently from a 28-year-old with contact lens sensitivity. We’re not being academic here — it changes our emollient selection, our fragrance decision (usually zero for eye products), and our preservative system.

Honestly, most brands underestimate how much the brief intake conversation shapes the final formula. We’ve had projects where the brand came in asking for a “peptide eye cream” and left the kickoff realizing they actually needed two SKUs: one for EU/US and a reformulated version for NMPA registration. That’s a cost and timeline conversation nobody wants to have at month four.

Formulation Parameters: The Numbers That Actually Matter #

Let’s talk specifics, because this is where periorbital formulation diverges sharply from general facial skincare.

pH is the first lever. We target 6.5–7.0 for most eye-area emulsions — close to the natural tear film pH of 7.1. Drop below 5.5 and you risk lacrimation response on first application. We’ve seen consumer complaint rates spike when eye creams come in below pH 5.8, even with otherwise clean formulations. Some brands push us toward lower pH to activate certain actives. We push back. The periorbital zone is not the place to optimize for acid-active ingredients.

Viscosity for an eye cream typically sits between 15,000–40,000 cP depending on format. A lightweight gel-cream for a mass-market brief might target the lower end; a rich night treatment for a premium positioning might go higher. What we don’t do is chase a texture target without checking spreadability under occlusion — the orbital bone creates a microclimate that traps heat and moisture, and a formula that feels elegant on the back of the hand can feel heavy and pilling around the eye after 20 minutes.

Preservative selection is where we spend the most time. Parabens are still the most effective option at 0.1–0.4% combined concentration, but a significant portion of our brand partners won’t use them — not because of safety data, which is actually solid under SCCS Scientific Opinion review — but because of consumer perception. So we work with phenoxyethanol at ≤1.0% (EU limit), often combined with ethylhexylglycerin at 0.3–0.5% to boost efficacy. The challenge at eye-area pH of 6.5–7.0 is that phenoxyethanol’s antimicrobial activity drops compared to lower pH systems. We compensate with tighter water activity control and sometimes chelation support via EDTA at 0.05–0.1%.

One failure we’ve learned from: a peptide eye serum we developed at 500g lab scale passed all challenge testing cleanly. At 200kg production, gram-negative organisms appeared at week 10 of stability. The culprit was a botanical extract that introduced trace contamination at scale — something the lab batch never saw because we were working from a different lot. We now require suppliers to provide microbial specs on every botanical ingredient, not just COAs for heavy metals and pesticides.

Active ingredient loading for periorbital products is deliberately conservative. Retinol, if used at all, stays at 0.025–0.05% — not the 0.1–0.3% we’d use in a facial serum. Caffeine for depuffing typically runs 1.0–3.0%. Niacinamide, if included, stays at 2.0–4.0% rather than the 5.0% we’d use elsewhere. The skin simply can’t tolerate the same loading. Brands sometimes push back on this, wanting to match the percentages on their facial serum. That’s usually where projects go sideways.

For a deeper look at how we handle retinoid actives in sensitive-zone applications, see our retinoid technology formulation guide.

Development Tiers: What You’re Actually Buying at Each Level #

This is the conversation most brands want to skip, but we insist on having it early. There is no universal “eye cream” — there’s a mass-market eye cream, a mid-tier eye cream, and a premium eye cream, and they are genuinely different products with different cost structures, timelines, and performance expectations.

The packaging cost difference between tiers is real and often surprises brands. A standard jar or tube for mass market might add $0.15–0.25 per unit. An airless pump — which we strongly recommend for any formula containing retinol or growth factors — adds $0.40–0.80 per unit. At MOQ 3,000 units, that’s a $1,200–$2,400 packaging premium before you’ve touched the formula cost. Most indie brands can’t absorb that at launch. We usually recommend starting with a laminated tube with a small airless secondary for hero SKUs, then transitioning to full airless at scale.

Encapsulation for sensitive actives sounds like a premium-only decision. It’s not always. We’ve had mass-market briefs where encapsulation was the only way to hit a 12-month stability target with retinol in an eye-area pH range. The cost is roughly 2.5–3× the raw material cost of the unencapsulated active. Sometimes it’s the right call even at lower price points. For more on when encapsulation makes sense versus when it doesn’t, see our encapsulation technology overview.

The Clinical Evidence Question #

Brands increasingly want clinical claims on eye products. We support that — but the data has to be real, and the study design has to match the claim.

The most cited study design for periorbital efficacy is a split-face, double-blind, placebo-controlled trial using standardized photography and optical profilometry. One study we reference frequently in our development briefs: a randomized controlled trial (n=44, 12 weeks, twice-daily application) evaluating a multi-peptide eye cream versus vehicle control. The peptide group showed a 27% reduction in crow’s feet wrinkle depth by profilometry and a 31% improvement in self-assessed puffiness at week 8. What that study doesn’t tell you — and what we’ve learned from our own batches — is that the stability of the peptide complex at pH 6.8 over 18 months is a separate challenge entirely. The clinical result is real. Replicating it in a stable commercial formula takes additional work.

We’re still not fully convinced the growth factor evidence for periorbital use is strong enough to justify the cost premium in most mass-market briefs. The in-vitro data is compelling. The in-vivo periorbital-specific data is thinner than suppliers will admit. We tell brands this upfront.

For brands targeting EU markets, any clinical claim needs to be substantiated under the EU Cosmetics Regulation 1223/2009 product information file. That means the study methodology, subject demographics, and statistical analysis all need to be documented and available for competent authority review. We build that documentation into our premium tier development process. It’s not optional if you’re selling in Germany, France, or the UK post-Brexit.

Where Most Brands Get This Wrong #

The brief says “clean, fragrance-free, ophthalmologist-tested eye cream.” Fine. But then the brand also wants a “luxurious sensory experience” with a “subtle floral note.” Those two briefs are in direct conflict, and we see this combination more than we should.

Fragrance in eye-area products is the single fastest way to generate consumer complaints and returns. Even at 0.1% — well below the IFRA limits for leave-on products — fragrance components can cause lacrimation, contact dermatitis, and milia in periorbital skin. We almost always push back on any fragrance inclusion in eye products. If the brand insists, we require a full IFRA compliance review and we cap the inclusion at 0.05% with restricted materials excluded entirely.

The other common mistake is over-engineering the active stack. We’ve had briefs come in with 12 actives listed for an eye serum. Peptides, retinol, vitamin C, caffeine, hyaluronic acid, niacinamide, ceramides, growth factors, plant stem cells, and two proprietary complexes. At that point, the formula is fighting itself. Vitamin C at any meaningful concentration destabilizes at eye-area pH. Retinol and niacinamide together in an eye-area formula require careful pH management to avoid the niacinamide-retinol interaction that generates nicotinic acid. We reject those briefs and ask the brand to prioritize three to four actives maximum.

A lot of clean beauty brands also underestimate how fragile low-pH preservative systems become at production scale. When you’re running 200kg batches with botanical extracts that introduce variable water activity, the preservative efficacy you validated at lab scale doesn’t always hold. This is still evolving — what passes challenge testing today may not hold through 18 months of real-time stability in all markets.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions in every eye-care kickoff we run, and the answers shape everything downstream.

If you’re launching in the EU first, we build the formula around the EU Cosmetics Regulation 1223/2009 restricted substances list from day one — not as an afterthought. That means no methylisothiazolinone, no formaldehyde releasers, and careful review of any fragrance allergens above 0.001% in leave-on products. If China is in scope, we flag the NMPA special-use pathway early and build the registration dossier in parallel with development, not after.

For timeline: a realistic mass-market eye cream from brief to pilot batch is 14–16 weeks. Mid-tier with ophthalmologist testing adds 4–6 weeks. Premium with full stability and clinical support is 24–30 weeks minimum. Brands that come to us expecting 8-week turnarounds on eye products with clinical claims are going to be disappointed, and we’d rather have that conversation now.

Budget for at least two formula iterations. In our experience, the first pilot batch reveals something — a texture issue, a stability flag, a packaging compatibility problem — that requires reformulation. Building that into the project plan from the start prevents the timeline compression that causes real quality problems later.

We haven’t fully solved the challenge of delivering high-concentration actives in eye-area formats without compromising tolerability. Our current approach works for most briefs, but it’s not elegant.

Frequently Asked Questions #

Q: We want to put “ophthalmologist-tested” on pack — what does that actually require from your side?

We run a standardized ocular tolerability protocol with a contracted ophthalmology clinic — typically 30 subjects, single application under observation, with follow-up at 24 and 72 hours. The test costs roughly $2,500–$4,000 depending on the clinic and scope. It doesn’t prove efficacy, just tolerability. If you want to add “clinically proven to reduce wrinkles,” that’s a separate study with a separate budget.

Q: Can we use retinol in an eye cream and still call it clean beauty?

Retinol itself isn’t on any major clean beauty restricted list. The issue is concentration and stability. We keep eye-area retinol at 0.025–0.05% and almost always encapsulate it. At that level, most clean beauty retailers will accept it. Above 0.1%, you start getting pushback from some platforms regardless of safety data.

Q: How long does NMPA registration take for an eye product with functional claims?

Realistically, 12–18 months from dossier submission for a special-use cosmetic. That’s assuming your dossier is complete on first submission, which requires a China-registered testing lab for safety and efficacy data. We build NMPA-ready documentation into our premium tier. If you’re planning a China launch within 12 months, you needed to start this process already.

Q: We’ve seen eye creams with 10% peptide concentration on competitor labels — why are you recommending 5–8%?

Label concentration and formula concentration are not always the same thing. A “10% peptide complex” might be 10% of a diluted proprietary blend, not 10% pure peptide. In our formulations, we work with active peptide concentrations of 3–8% because that’s the range where we can maintain stability at pH 6.5–7.0 over 18 months. Higher concentrations introduce osmotic stress on the emulsion system and we’ve seen phase separation at month 6 in accelerated testing above 9%.

Q: What’s the minimum order quantity for a custom eye cream development?

Our standard MOQ for a custom-developed eye cream is 3,000 units for the first production run. Development fee is separate and covers formulation, stability initiation, and pilot batch. If you’re testing market fit with a smaller quantity, we can discuss a white-label adaptation of an existing base formula, which reduces MOQ to 1,000 units but limits customization of the active stack.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.